Development and Evaluation of Multiple-Unit Tablets for the Controlled Release of Lornoxicam [0.03%]
布洛昔康控制释放多单元片剂的开发与评价
Yang Liu,Qiong-Zhi Shi,Yanchen Wang et al.
Yang Liu et al.
Background and objective: Lornoxicam (LOX) is a nonsteroidal anti-inflammatory drug used for pain management but requires frequent dosing due to its short half-life. This study aimed to develop a biphasic-release multiple...
Advanced Drug Delivery Strategies for Overcoming Biological Barriers: Tumor Microenvironment and Blood-Brain Barrier [0.03%]
克服生物屏障的先进药物递送策略：肿瘤微环境和血脑屏障
Yicong Lei,Tingyu Xiao,Xin Hu et al.
Yicong Lei et al.
Therapeutic efficacy for malignancies and neurological disorders is fundamentally restricted by biological barriers, particularly the complex tumor microenvironment (TME) and selective blood-brain barrier (BBB). This review analyzes advance...
Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile [0.03%]
AHT-102的药代动力学、抗肿瘤疗效、组织分布和安全性研究
Huilun Chu,Guili Xu,Yunlong Liu et al.
Huilun Chu et al.
Background and objectives: Claudin18.2 (CLDN18.2) is a promising therapeutic target overexpressed in various tumor tissues. While CD3-engaging bispecific antibodies show great potential, their clinical application is ofte...
Pharmacokinetics, Pharmacodynamics, and Safety of ET-26 in Subjects with Mild to Moderate Renal Impairment [0.03%]
ET-26在轻度至中度肾功能不全受试者中的药代动力学、药效学和安全性
Fan Yang,Chao-Zhuang Shen,Pan-Pan Ye et al.
Fan Yang et al.
Background and objectives: ET-26 is a novel etomidate analog with reduced adrenal suppression. This study evaluated its pharmacokinetics (PK), pharmacodynamics (PD), and safety in subjects with mild to moderate renal impa...
Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance [0.03%]
奥马达仙的药代动力学：特征、影响因素及临床意义
Huan Sun,Xiaoli Hou,Qiuzhen Zhu et al.
Huan Sun et al.
Omadacycline is a novel tetracycline with a wide range of antibacterial activity. A comprehensive understanding of the factors influencing its metabolic processes is essential to optimize its therapeutic benefits and minimize any potential ...
Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Omecamtiv Mecarbil in Healthy Chinese Subjects [0.03%]
一项多剂量递增研究，评估奥马西普在中国健康受试者中的安全性、耐受性和药代动力学特征
Xuening Li,Hui Li,Hongrong Xu et al.
Xuening Li et al.
Background and objectives: This phase I study was designed to evaluate the safety, tolerability, and pharmacokinetics of omecamtiv mecarbil with multiple oral doses at 25 mg twice daily, followed by titration to either 37...
Safety, Tolerability and Pharmacokinetics of a High-Dose, Rapid-Infusion Monoclonal Antibody: Phase I Results for Intravenous Sotrovimab 3000 mg [0.03%]
单次静脉注射高剂量（3000毫克）苏特科维姆аб的安全性、耐受性和药代动力学：I期临床研究结果
Yasmin Sánchez-Pearson,Jennifer Moore,Jerzy Daniluk et al.
Yasmin Sánchez-Pearson et al.
Background and objectives: The emergence of severe acute respiratory syndrome coronavirus 2 variants against which sotrovimab has lower in vitro neutralisation activity has led to the exploration of higher (> 500-mg intra...
Safety, Tolerability, Pharmacokinetics, and Viral Pharmacodynamics of the Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection in Participants with Early, Mild-to-Moderate COVID-19: A Randomized Clinical Trial [0.03%]
轻至中度新冠肺炎患者的早期肌肉注射单克隆抗体索托维单抗的安全性、耐受性、药代动力学和病毒药理动力学：一项随机临床试验
Anil Gupta,Maria Teresa Perez-Rodríguez,Yaneicy Gonzalez-Rojas et al.
Anil Gupta et al.
Background and objectives: New coronavirus disease 2019 (COVID-19) therapeutics, including intramuscular (IM) formulations, may increase patient access. In COMET-TAIL, sotrovimab 500 mg IM was non-inferior to 500 mg intra...
Bioequivalence of Two Perampanel Oral Suspension Formulations in Healthy Subjects: A Randomized Crossover Study [0.03%]
布南色林两种口服混悬液剂型在健康受试者中的生物等效性：一项随机交叉试验
Aya M AbdelMagid,Kamal A Badr,Mamdouh R Rezk
Aya M AbdelMagid
Background and objective: Perampanel has been approved for the adjunctive treatment of partial-onset seizures and primary generalized tonic-clonic seizures. The oral suspension formulation benefits patients who have diffi...